Novimmune unit nabs Takeda milestone payment for hemophilia work

Takeda HQ
The original deal with Light Chain Bioscience, a unit of Swiss biotech Novimmune, was penned with Shire in 2017 but now continues under new owner Takeda. (Takeda)

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda Pharmaceutical.

The competitive hemophilia A market has seen a lot of intensity in R&D in the past few years, with a focus now on gene therapies. Light Chain Bioscience is focusing its efforts on bispecifics as it hopes to challenge Roche’s bleeding drug Hemlibra, also a bispecific that works as a factor IXa- and factor X-directed antibody. It’s seen top sales estimates of $5 billion a year at peak.

The biotech’s milestone was “achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific antibodies as clinical development candidates with approval to advance to IND-enabling studies,” the company said, though extra details and money paid were not being shared.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

The collab is designed to create bispecific antibodies with factor VIII mimetic activity for the treatment of hemophilia A patients.

The original pact was signed under Shire, which has since been snapped up by the Japanese Big Pharma. Under the 2017 deal, Shire (now Takeda) nabbed rights to develop and sell the drug. The endgame is to create a product that is better and safer than the current factor class.

Financials were not disclosed.

The European company has been developing a platform for making fully human, bispecific antibodies and has several in-house programs targeting tumor-associated antigens and immune system checkpoint protein CD47. The biotech and Shire first struck an R&D collaboration back in 2015.

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.